MedTrace Logo

Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease

NCT02176434 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-12-01

No results posted yet for this study

Summary

This pilot study of combined kidney and hematopoietic stem cell transplantation attempts to establish a protocol to induce immunological tolerance as a new strategy to prevent renal graft rejection. If successful, this strategy would restore renal function, while avoiding the risks associated with long-term standard anti-rejection therapy, and would represent the first option to cure end-stage renal disease.

Conditions

Interventions

PROCEDURE

Kidney and hematopoietic stem cell transplantation

Kidney transplantation (day 0) Induction therapy (s. above) Hematopoietic stem cell transplantation (s. above)

BIOLOGICAL

hematopoietic stem cell

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Thomas Ferh, MD · University of Zurich

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02176434 on ClinicalTrials.gov